HGH Fragment 176-191 vs PE-22-28
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
HGH Fragment 176-191Cognitive Enhancement
PE-22-28- Summary
- HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
- PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
- Half-Life
- ~30 minutes
- Relatively short; CNS effects may persist due to neurogenic mechanisms
- Admin Route
- SubQ
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 250–500 mcg
- 200–400 mcg
- Frequency
- 1–3 times daily
- Once daily
- Key Benefits
- Selective fat burning without anabolic side effects
- Reduces visceral and subcutaneous fat
- No insulin resistance or blood glucose disruption
- Does not stimulate IGF-1
- May support cartilage and bone repair (at higher doses)
- No effect on growth or organ size
- Rapid-onset antidepressant effects (within 24 hours)
- Promotes hippocampal neurogenesis
- Improves cognitive performance and memory
- Reduces anxiety and depressive behavior
- Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
- May help treatment-resistant depression
- Neuroprotective effects
- Side Effects
- Injection site irritation
- Temporary lethargy
- Headache (rare)
- Nausea (rare)
- Generally well tolerated in animal models
- Limited human data available
- Possible mild headache or transient mood changes at initiation
- Injection site reactions (SC)
- Stacks With
- —
- —